Absci Corporation (ABSI)

Over the past six months (October 2025 - April 2026), Absci's stock has experienced several events and fluctuations. The stock price saw a 20.16% increase over the past year, but a 25.87% decline over the past six months. In November 2025, Absci reported its Third Quarter 2025 financial and operating results, announced interim results for the Phase 1 trial for ABS-101, accelerated the initiation of the Phase 1/2a trial for ABS-201 for androgenetic alopecia to December 2025, and expanded the ABS-201 strategy to pursue endometriosis as an additional indication, anticipating a Phase 2 clinical trial in Q4 2026. In December 2025, H.C. Wainwright raised their target price on Absci from $7.00 to $8.00 and maintained a "buy" rating. In January 2026, Morgan Stanley downgraded Absci from an "overweight" rating to an "equal weight" rating and set a $4.32 target price, and Weiss Ratings reissued a "sell (d-)" rating. In February 2026, CEO Sean McClain sold 26,761 shares of the firm's stock. In March 2026, Absci reported its Fourth Quarter and Full Year 2025 financial and operating results, successfully dosed the first three cohorts in the SAD portion of the ABS-201 HEADLINE trial, unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates the follicle stem cell niche, appointed Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer, Needham & Company LLC reissued a "buy" rating and a $7.00 target price, and insider Andreas Busch bought 100,000 shares. In April 2026, Absci announced participation in the 25th Annual Needham Virtual Healthcare Conference.

Based on available information, there is no explicit indication of demand seasonality for Absci Corp.'s products and services in the traditional sense of consumer goods. As a biotechnology company focused on drug discovery and development, demand for its platform and therapeutic candidates is driven by ongoing research, pharmaceutical partnerships, and the progression of clinical trials, rather than seasonal consumer trends. However, an analysis of ABSI's historical stock price data suggests that October has historically offered the highest probability of positive returns at 80.00%, while April may not be an ideal month to invest, with a 20.00% probability of a positive return. This seasonality, however, relates to stock performance rather than the demand for its core business offerings.

Absci Corporation is a clinical-stage biotechnology company specializing in AI drug creation, leveraging artificial intelligence (AI) and synthetic biology to accelerate drug discovery and development. The company operates within the biotechnology and pharmaceutical sectors, focusing on AI-Driven Drug Discovery and Synthetic Biology and Biomanufacturing. Absci's core mission is to redefine the drug discovery process by integrating cutting-edge AI technologies with innovative biological systems to create new therapeutics faster and more efficiently. Absci's key offering is its Integrated Drug Creation™ platform, which combines AI models with scalable wet lab technologies to design and validate biologic drug candidates. This platform aims to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics. The company's business model generates revenue through collaborations and partnerships with pharmaceutical and biotechnology companies, licensing agreements for its technologies, and service contracts for research and development. Major products and programs in Absci's pipeline include ABS-201, an anti-prolactin receptor antibody in Phase 1/2a clinical trial for androgenetic alopecia and being investigated for endometriosis; ABS-101, a preclinical development program in Phase 1 clinical trial for inflammatory bowel disease; ABS-301, a potential first-in-class antibody for an undisclosed immuno-oncology target; and ABS-501, a potential best-in-class novel AI-designed anti-HER2 antibody for oncology. The company also has approximately nine active programs, with eight focused on developing production cell lines for drug candidates being developed by its partners, and one discovery program in lead optimization with Astellas.

Absci Corporation is headquartered in Vancouver, Washington, USA. The company also has AI Research Labs located in New York City and Serbia, and an Innovation Center in Zug, Switzerland.

Absci positions itself as a pioneering biotechnology company that combines AI and synthetic biology to revolutionize drug discovery and development. The company emphasizes its commitment to sustainability in biomanufacturing practices. Recent developments, such as AI platform enhancements and new strategic partnerships with leading pharmaceutical companies, contribute positively to its reputation. The company's focus on advancing its clinical-stage programs, like ABS-201 for androgenetic alopecia and endometriosis, and its ability to secure collaborations, are key factors in how investors and analysts evaluate its standing. Events that have affected Absci's reputation in the past year largely revolve around its financial performance and clinical trial progress. While the company has highlighted favorable emerging safety data for ABS-201 and expanded collaborations, it has also reported widening losses due to heavy investment in its AI-driven drug pipeline and R&D expenses. Absci missed analysts' EPS and revenue expectations in its Q4 2025 earnings report. Analyst ratings have been mixed, with some downgrades and reissued "sell" ratings alongside "buy" recommendations and raised price targets.

Absci Corporation's stock is primarily held by institutional investors, who own approximately 67% to 78.29% of the company. Insiders own around 6.81% to 33.01% of the stock, while retail investors hold about 20% to 24.81%. Major institutional owners include Fmr Llc, ARK Investment Management LLC, BlackRock, Inc., Redmile Group, LLC, Vanguard Group Inc, State Street Corp, Advanced Micro Devices Inc, Geode Capital Management, Llc, Ameriprise Financial Inc, and UBS Group AG. Sean McClain, the founder and CEO, holds about 6.8% of the company stock and is also a Member of the Board of Directors.